CN100339073C - 作为血清素拮抗剂用于治疗肥胖的芳基磺酰胺 - Google Patents

作为血清素拮抗剂用于治疗肥胖的芳基磺酰胺 Download PDF

Info

Publication number
CN100339073C
CN100339073C CNB018131506A CN01813150A CN100339073C CN 100339073 C CN100339073 C CN 100339073C CN B018131506 A CNB018131506 A CN B018131506A CN 01813150 A CN01813150 A CN 01813150A CN 100339073 C CN100339073 C CN 100339073C
Authority
CN
China
Prior art keywords
alkyl
alkoxyl
formula
hydroxyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018131506A
Other languages
English (en)
Chinese (zh)
Other versions
CN1443161A (zh
Inventor
P·卡尔迪罗拉
S·乔森
K·S·萨卡利亚森
J·斯沃滕伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum AB filed Critical Biovitrum AB
Publication of CN1443161A publication Critical patent/CN1443161A/zh
Application granted granted Critical
Publication of CN100339073C publication Critical patent/CN100339073C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB018131506A 2000-07-21 2001-07-19 作为血清素拮抗剂用于治疗肥胖的芳基磺酰胺 Expired - Fee Related CN100339073C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002739A SE0002739D0 (sv) 2000-07-21 2000-07-21 New use
SE00027391 2000-07-21

Publications (2)

Publication Number Publication Date
CN1443161A CN1443161A (zh) 2003-09-17
CN100339073C true CN100339073C (zh) 2007-09-26

Family

ID=20280564

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018131506A Expired - Fee Related CN100339073C (zh) 2000-07-21 2001-07-19 作为血清素拮抗剂用于治疗肥胖的芳基磺酰胺

Country Status (16)

Country Link
EP (1) EP1301475B1 (enExample)
JP (1) JP2004504377A (enExample)
KR (2) KR100880806B1 (enExample)
CN (1) CN100339073C (enExample)
AT (1) ATE346040T1 (enExample)
AU (2) AU2001271225B2 (enExample)
CA (1) CA2411195A1 (enExample)
CY (1) CY1106026T1 (enExample)
DE (1) DE60124717T2 (enExample)
DK (1) DK1301475T3 (enExample)
ES (1) ES2277930T3 (enExample)
NO (1) NO20030297L (enExample)
NZ (1) NZ523158A (enExample)
PT (1) PT1301475E (enExample)
SE (1) SE0002739D0 (enExample)
WO (1) WO2002008179A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0204720D0 (en) * 2002-02-28 2002-04-17 Glaxo Group Ltd Novel use
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
PA8802201A1 (es) 2007-11-02 2009-06-23 Abbott Gmbh & Co Kg Compuestos de bencensulfonalida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6
MX2011011519A (es) 2009-04-30 2012-01-30 Abbott Gmbh & Co Kg Compuestos de bencensulfonanilida adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
US8362010B2 (en) 2009-04-30 2013-01-29 Abbott Gmbh & Co. Kg Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
CN102459197B (zh) 2009-04-30 2015-08-19 Abbvie公司 适用于治疗响应血清素5-ht6受体的调节的病症的n-苯基-(哌嗪基或高哌嗪基)-苯磺酰胺或苯磺酰基-苯基-(哌嗪或高哌嗪)化合物
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
ES2413911B1 (es) * 2011-12-15 2014-05-14 Universidad De Zaragoza Agente inhibidor de la agregación del peptido beta amiloide.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611003A1 (en) * 1993-02-09 1994-08-17 Merck & Co. Inc. Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity
EP0815861A1 (de) * 1996-06-28 1998-01-07 F. Hoffmann-La Roche Ag Sulfonamide und ihre Verwendung
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments
WO1999002502A2 (en) * 1997-07-11 1999-01-21 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
WO1999042465A2 (en) * 1998-02-18 1999-08-26 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
CN1247537A (zh) * 1996-12-27 2000-03-15 克诺尔有限公司 具有5－ht受体活性的磺酰胺化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11171856A (ja) * 1997-09-26 1999-06-29 Fujirebio Inc アシルスルホンアミド誘導体
CA2315614C (en) * 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611003A1 (en) * 1993-02-09 1994-08-17 Merck & Co. Inc. Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity
EP0815861A1 (de) * 1996-06-28 1998-01-07 F. Hoffmann-La Roche Ag Sulfonamide und ihre Verwendung
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments
CN1247537A (zh) * 1996-12-27 2000-03-15 克诺尔有限公司 具有5－ht受体活性的磺酰胺化合物
WO1999002502A2 (en) * 1997-07-11 1999-01-21 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
WO1999042465A2 (en) * 1998-02-18 1999-08-26 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation

Also Published As

Publication number Publication date
DK1301475T3 (da) 2007-04-02
DE60124717D1 (de) 2007-01-04
AU2001271225B2 (en) 2006-09-07
HK1057886A1 (zh) 2004-04-23
PT1301475E (pt) 2007-02-28
JP2004504377A (ja) 2004-02-12
EP1301475A1 (en) 2003-04-16
NO20030297D0 (no) 2003-01-20
NZ523158A (en) 2004-04-30
EP1301475B1 (en) 2006-11-22
CY1106026T1 (el) 2011-04-06
ES2277930T3 (es) 2007-08-01
SE0002739D0 (sv) 2000-07-21
KR100828977B1 (ko) 2008-05-13
CA2411195A1 (en) 2002-01-31
WO2002008179A1 (en) 2002-01-31
NO20030297L (no) 2003-01-20
CN1443161A (zh) 2003-09-17
KR20080016725A (ko) 2008-02-21
KR20030016413A (ko) 2003-02-26
DE60124717T2 (de) 2007-09-13
ATE346040T1 (de) 2006-12-15
AU7122501A (en) 2002-02-05
KR100880806B1 (ko) 2009-01-30

Similar Documents

Publication Publication Date Title
KR101890450B1 (ko) Ｃｎｓ 장애의 치료에 사용되는 브렉스피프라졸 또는 이의 염 및 2 차 약물을 포함하는 조합물
CN100339073C (zh) 作为血清素拮抗剂用于治疗肥胖的芳基磺酰胺
ES2237110T3 (es) Uso de (+)-norcisaprida opticamente pura para tratar el sindrome del intestino irritable.
JPH11510828A (ja) 光学的に純粋な（＋）ノルシサプリドを用いた嘔吐および中枢神経系障害の治療方法
JPH08502031A (ja) 胃食道逆流疾患およびその他の障害を治療するために▲（＋）▼シサプリドを使用する方法
JP2001503394A (ja) 神経障害または神経精神障害の処置法
AU670518B2 (en) Methods for treating resistant neoplasms
BRPI0610028A2 (pt) combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos
EP0483152A1 (en) A method of reducing body weight and food intake using a dopamine d2 receptor agonist
CN1320036A (zh) 治疗胃－食管返流性疾病的方法和组合物
CN1642532A (zh) 曲马多缓释制剂
AU2001271225A1 (en) Aryl sulfonamides as serotonin antagonist for the treatment of obesity
CN1264512C (zh) 含有氨基噻唑衍生物、用于治疗结肠运动功能障碍的药用组合物
US5234945A (en) Method of producing body weight and food intake using a dopamine D2 receptor agonist
CN101076328A (zh) 用于睡眠障碍的预防或治疗剂
US20020058655A1 (en) New use
KR20010099648A (ko) 신규 조성물
US6596759B2 (en) Medicament for treatment of irritable bowel syndrome
HK1057886B (en) Aryl sulfonamides as serotonin antagonist for the treatment of obesity
WO2001093844A2 (en) Compositions comprising a serotonin transporter inhibitor and a 5-ht1d antagonist
CN1631363A (zh) 黄瘤病的预防、治疗剂
AU2024276707A1 (en) Pharmaceutical compositions comprising 2,3,4,5-tetrahydro-benzothiepin-1,1-dioxide derivatives and the use thereof
Chan et al. Development of Novel Melatoninergics as Circadian Rhythm Sleep Disorder Therapeutics
JP2008255058A (ja) 睡眠障害予防治療剤
WO2007003741A2 (fr) Composes de type polyphenols, les compositions les contenant et leur utilisation pour prevenir ou traiter des maladies impliquant une proliferation cellulaire anormale

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1057886

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070926

Termination date: 20100719